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Simple Summary: Risk stratification using genetic testing to identify women at increased
risk of ovarian cancer may increase the number of patients to whom risk-reducing surgery
(e.g., salpingo-oophorectomy) may be offered. However, little is known about public acceptability
of such approaches. Our online experimental survey aimed to explore whether women aged 45–75
in the general population are willing to undergo ovarian cancer risk assessment, including genetic
testing, and whether women’s potential acceptance of risk-reducing surgery differs depending
on their estimated risk. We looked at whether psychological and cognitive factors mediated
women’s decision-making. The majority of participants would be interested in having genetic testing.
In response to our hypothetical scenarios, a substantial proportion of participants were open to the
idea of surgery to reduce risk of ovarian cancer, even if their absolute lifetime risk is only increased
from 2% to 5 or 10%.
Abstract: Risk stratification using genetic and/or other types of information could identify women at
increased ovarian cancer risk. The aim of this study was to examine women’s potential reactions
to ovarian cancer risk stratification. A total of 1017 women aged 45–75 years took part in an online
experimental survey. Women were randomly assigned to one of three experimental conditions
describing hypothetical personal results from ovarian cancer risk stratification, and asked to imagine
they had received one of three results: (a) 5% lifetime risk due to single nucleotide polymorphisms
(SNPs) and lifestyle factors; (b) 10% lifetime risk due to SNPs and lifestyle factors; (c) 10% lifetime risk
due to a single rare mutation in a gene. Results: 83% of women indicated interest in having ovarian
cancer risk assessment. After receiving their hypothetical risk estimates, 29% of women stated they
would have risk-reducing surgery. Choosing risk-reducing surgery over other behavioural responses
was associated with having higher surgery self-efficacy and perceived response-efficacy, but not
with perceptions of disease threat, i.e., perceived risk or severity, or with experimental condition.
A substantial proportion of women age 45–75 years may be open to the idea of surgery to reduce risk
of ovarian cancer, even if their absolute lifetime risk is only increased to as little as 5 or 10%.
Keywords: risk stratification; genomics; questionnaires; attitudes
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1. Introduction
Ovarian cancer is the sixth most common cancer among women in the UK. The general population
lifetime risk of developing ovarian cancer is approximately 2%, and incidence is predicted to rise by
26% in the UK, 14% in Europe, and by 55% worldwide over the next two decades [1]. The risk of
ovarian cancer rises with age, increasing significantly in women over 45 years [2]. DNA variants in a
number of cancer susceptibility genes are known to be associated with ovarian cancer: women with a
high penetrance genetic variant, such as a BRCA1 or BRCA2 mutation, are considered to be at high risk
for developing breast and ovarian cancer [3–5]. Historically, genetic testing for ovarian cancer risk has
been clinically indicated only for women with a strong family history of breast and/or ovarian cancer.
However, using a family history based approach misses over half the cancer susceptibility gene (CSG)
carriers at risk [6,7], and is associated with restricted access and limited utilization of genetic testing [8].
Additionally, the majority of cases of ovarian cancer do not occur in affected families [9]. There is
increasing interest in the idea of adopting a risk-stratified approach to ovarian cancer prevention by
offering genetic testing to all women regardless of family history [10–12].
In addition to rare variants of high penetrance, genome-wide association studies have to date
identified a number of common single nucleotide polymorphisms (SNPs) associated with slightly
increased risk of ovarian cancer [13]. SNP-based information and certain lifestyle factors each increase
ovarian cancer risk by a small amount individually, but this becomes clinically significant when
the information is combined, e.g., from 2% to between 5% and 10% lifetime risk [9,14,15]. Surgical
prevention has been shown to be cost-effective at the 4–5% ovarian cancer risk threshold [16,17].
Newer risk models and recently validated intermediate risk genes can identify individuals at these
risk thresholds. Risk stratification using multigene testing to identify women at increased risk of
ovarian cancer is potentially more cost- and time-effective than single gene testing and increases the
number of patients to whom risk-reducing surgery (e.g., salpingo-oophorectomy) may be offered [18].
While clinical practice has gradually begun to change [19], data on public acceptability of such
approaches are limited.
An initial quantitative study assessing attitudes towards population-based genetic testing for
ovarian cancer risk in a general population sample found high levels of support for risk-stratified
ovarian cancer screening based on prior genetic risk assessment [20]. There is good evidence to suggest
that population-wide genetic testing for ovarian cancer is acceptable, feasible and cost-effective amongst
Ashkenazi Jewish populations [6,7,21–23]. Preliminary data from the general population also indicate
that population-based personalised ovarian cancer risk stratification is feasible, acceptable, has high
satisfaction, reduces cancer worry/risk perception, and does not negatively impact psychological health
or quality of life [12].
Bilateral risk-reducing salpingo-oophorectomy (surgical removal of the ovaries and fallopian tubes,
hereafter referred to as “risk-reducing salpingo-oophorectomy” or “RRSO”) is currently recommended
as the main and most effective preventative strategy for ovarian cancer in women at increased risk of
ovarian cancer such as BRCA mutation carriers. RRSO can reduce ovarian cancer risk by 85–90% [24].
Traditionally the most common group of women undergoing surgical prevention have been BRCA
carriers, who have a 17–44% lifetime risk of ovarian cancer [5,25]. In the UK, women with an estimated
lifetime ovarian cancer risk of greater than 10%, who have completed their families, have traditionally
been offered risk-reducing surgery [15]. Undertaking surgery on the basis of family history alone in
the absence of a known mutation (at lower than BRCA levels of risk) has thus been clinical practice
in the UK and other countries for many years [25,26]. Recently, the 10% threshold was relaxed to
4–5% [14,15]. A number of new ovarian cancer risk genes have been identified, such as RAD51C
(lifetime risk 11%) [27], RAD51D (lifetime risk 13%), PALB2 (lifetime risk 5%) [28], and BRIP1 (lifetime
risk 5.8%) [29], testing for which is part of routine clinical practice. RRSO is now offered and being
undertaken for these CSGs too. Thus a number of clinical teams now offer RRSO to women in the
“intermediate” risk category (5–10%) as well as those in the “high” risk category (over 10%) [15].
Additionally, more complex models using SNP profiles, in combination with other epidemiological
Cancers 2020, 12, 3543 3 of 21
and genetic risk factors, are being validated, which will provide absolute lifetime risk estimates in
these ranges in the not too distant future [12].
National screening programmes for ovarian cancer are unavailable. In a large randomised
control trial designed to establish the effect of early detection by ovarian screening in the general
low-risk population, no conclusive significant impact on mortality from ovarian cancer was found [30],
and definitive mortality data are awaited in 2021. Surveillance for those identified as high-risk
(or in some cases moderate-to-high-risk) for ovarian cancer currently consists of serial 3–4 monthly
serum CA125 (Cancer Antigen 125 protein; a tumour marker) measurement (and annual transvaginal
ultrasound) aiming to detect pre-symptomatic cancer in the earlier stages and/or low volume disease
where treatment is more effective [31]. This 4 monthly longitudinal CA125 biomarker driven surveillance
strategy, using the risk of the ovarian cancer (ROCA) algorithm, may be beneficial in women at high risk
of ovarian cancer [31]. We have shown that this is associated with a significant stage shift, which can
be a surrogate for improved survival [31]. Identifying those at increased risk using a population wide
risk-stratified approach may result in more timely risk reduction options and could have a significant
impact on disease burden: modelling suggests that 13% of the female UK population have greater
than 4% lifetime risk and 9% have greater than 5% lifetime risk [15]. Manchanda et al. (2018) suggest
that, based on National Institute for Health and Care Excellence (NICE) cost-effectiveness guidelines,
risk-reducing surgery may be cost effective for postmenopausal women over the age of 50, with a
lifetime ovarian cancer risk of ≥5%. Wider implementation of targeted surgical prevention for women
at greater than 4–5% lifetime risk threshold provides a huge opportunity for cost-effective targeted
primary prevention.
Offering risk stratification to women in the general population, including communicating personal
ovarian cancer risk information and offering risk-reducing surgery, has the potential to be a feasible
way to reduce ovarian cancer mortality and reduce the population burden of the disease. However,
risk stratification will only lead to improved ovarian cancer prevention and early diagnosis if women
whose results indicate increased risk take action to reduce their risk. Women with a family history
of breast and ovarian cancer have been found to opt for risk reduction surgery, e.g., among BRCA1
and BRCA2 mutation carriers, the majority underwent risk-reducing surgery (salpingo-oophorectomy)
after their risk was communicated to them [25,32]. However, although quite a lot is known about
how genetic risk information impacts psychological wellbeing and behaviours among women from
families affected with ovarian (and/or breast) cancer, less is known about how women in the wider
non-Jewish population might react to being informed they have an increased genetic risk of ovarian
cancer [33–37]. Further research is needed to determine how women in the general population might
respond if presented with ovarian cancer risk information indicating they are at high risk based on
genetic as well as other risk factors.
Based on research prior to 2016, the evidence does not support the hypothesis that communicating
CSG-based risk estimates motivates lifestyle behaviour changes [33,38]. CSG-based risk information
also has not been associated with negative psychological outcomes [7,33,38,39]. More recently, a nested
study within the Predicting Risk of Cancer at Screening (PROCAS) study was conducted comparing
the psychological impact of providing women with personalised breast cancer risk estimates based
on: (a) the Tyrer–Cuzick (T–C) risk algorithm including breast density, or (b) T–C including breast
density plus SNPs, versus (c) comparison women awaiting results. This study found little evidence of
either psychological harm or of differences between women provided with risk estimates based on
SNPs versus others. However, women categorised as high-risk were excluded from the study, so no
conclusions could be drawn regarding high-risk results specifically. It remains to be seen whether
the source of the risk may have impacted psychological factors or if it had an effect on acceptance
of the risk information in this study [40]. In another recent study that examined the impact of
returning secondary findings (including BRCA1/2) from genomic sequencing to unselected populations,
few adverse psychological effects were found [41].
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As an initial step to providing some empirical data on the question of how women in the general
population might respond to personal ovarian cancer risk information indicating increased risk
(as against moderate risk [40]), we conducted an experimental survey study with women in the general
population, using the Extended Parallel Process Model (EPPM) [42] as our theoretical framework,
and to inform our selection of variables and measures. The EPPM is a social cognition model of
information processing and behaviour: it posits that how individuals react to threatening information
is informed by (a) their perceptions of the threat (perceived risk or susceptibility, and perceived
severity), and (b) their perceptions of the recommended action to reduce the threat (self-efficacy,
i.e., their confidence in their ability to carry out the recommended behaviour, and perceived response
efficacy, i.e., their confidence that the recommended behaviour will effectively reduce the threat to
their health).
Our specific aims were to: (1) explore whether women in the general population are willing to
undergo ovarian cancer risk assessment which includes genetic testing; (2) examine whether women’s
potential acceptance of risk-reducing surgery differs depending on whether their estimated risk is 5%
or 10%; (3) examine whether women’s potential acceptance of risk-reducing surgery differs depending
on whether their estimated risk is based on a single rare genetic variant of high penetrance or a more
complex combination of genetic and non-genetic factors. We also explored whether threat and efficacy
cognitions mediated any observed between-group differences, and examined the associations between
these cognitions (threat, efficacy) and acceptance of risk-reducing surgery in the sample overall.
2. Results
2.1. Sample Characteristics
Table 1 provides an overview of the participant characteristics. Age ranged from 45 to 75 years
with a mean of 57.50 (SD = 8.13). The majority were White (95.6%) with 3.8% from other ethnic
backgrounds. Educational attainment was fairly evenly split between General Certificate of Secondary
Education (GCSE) or equivalent (34.6%), A levels or equivalent (23.8%), and undergraduate degree or
equivalent (24.1%). The majority (85.2%) of women were either perimenopausal (beginning menopause)
or post-menopausal. See Figure 1 for the Consolidated Standards of Reporting Trials (CONSORT) flow
diagram of participants throughout the study.
Table 1. Sample characteristics and interest in genetic testing overall and in each randomised
experimental group (total n = 1017).
Variables
Group 1:
5% SNPs and Lifestyle
(n = 340)
Group 2:
10% SNPs and Lifestyle
(n = 343)
Group 3:
10% Rare Genetic Variant
(n = 334)
Demographics n (%)
Age Mean (SD) 57.43 (8.32) 57.37 (7.78) 58.08 (8.19)
Age group
45–50 89 (26.2) 82 (23.9) 73 (21.9)
51–55 71 (20.9) 66 (19.2) 67 (20.1)
56–60 59 (17.4) 70 (20.4) 65 (19.5)
61–65 53 (15.6) 70 (20.4) 61 (18.3)
66–70 42 (12.4) 34 (9.9) 38 (11.4)
71–75 26 (7.6) 21 (6.1) 30 (9.0)
Ethnicity
White (Any background) 327 (96.2) 324 (94.5) 321 (96.1)
Other ethnic group 11 (3.2) 17 (5.0) 11 (3.3)
Educational Attainment
No Formal Qualification 26 (7.6) 23 (6.7) 17 (5.1)
GCSE or equivalent 115 (33.8) 126 (36.7) 111 (33.2)
A-Levels or equivalent 75 (22.1) 80 (23.3) 87 (26.0)
Undergraduate degree/equivalent 89 (26.2) 77 (22.4) 79 (23.7)
Postgraduate degree/equivalent 31 (9.1) 30 (8.7) 31 (9.3)
Other 4 (1.2) 7 (2.0) 9 (2.7)
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Table 1. Cont.
Variables
Group 1:
5% SNPs and Lifestyle
(n = 340)
Group 2:
10% SNPs and Lifestyle
(n = 343)
Group 3:
10% Rare Genetic Variant
(n = 334)
Relationship Status
Married/Cohabiting/In a relationship 245 (72.1) 232 (67.6) 233 (69.8)
Single/Separated/divorced/widowed 93 (27.4) 111 (32.4) 99 (29.6)
Health Characteristics
Menopause status
Premenopausal 41 (12.1) 37 (10.8) 43 (12.9)
During/post menopause 283 (83.2) 298 (86.9) 285 (85.3)
Personal History of Cancer
Yes 17 (5.0) 16 (4.7) 17 (5.1)
No/Not sure 323 (95.0) 327 (95.3) 317 (94.9)
Family History of Cancer
Yes 214 (62.4%) 206 (59.7%) 201 (58.8%)
No/Not sure 129 (37.6%) 139 (40.3%) 141 (41.2%)
Cervical Screening
Regular 192 (72.7) 214 (76.7) 179 (67.8)
Irregular 72 (27.3) 65 (23.3) 85 (32.2)
Not eligible 58 (17.1) 44 (12.8) 62 (18.6)
Breast Screening
Regular 196 (81.0) 201 (79.4) 196 (79.7)
Irregular 46 (19.0) 52 (20.6) 50 (20.3)
Not eligible 72 (21.2) 59 (17.2) 61 (18.3)
Interest in ovarian cancer risk
assessment
Yes Definitely 139 (40.9) 122 (35.6) 125 (37.4)
Yes Probably 151 (44.4) 156 (45.5) 153 (45.8)
No Probably not 36 (10.6) 46 (13.4) 46 (13.8)
No definitely not 14 (4.1) 19 (5.5) 10 (3.0)
SNPs: single nucleotide polymorphisms; SD: standard deviation; GCSE: General Certificate of Secondary Education.
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2.2. Interest in Ovarian Cancer Risk Assessment
Overall, 83.2% of women indicated they would “yes definitely” (38.0%) or “yes probably” (45.2%)
have an ovarian cancer risk assessment if it was offered to them by their general practitioner (GP) on
the National Health Service (NHS) (see Table 1 and Figure 2).
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2.4. Differences by Experimental Condition
Women’s intentions to have risk-reducing surgery did not differ significantly between the 5% and
10% multifactorial SNPs + lifestyle groups (27.9% vs. 26.2%, respectively) (χ2(1) = 0.314, p = 0.61).
Women who received a 10% risk result based on a rare genetic variant were no more likely to opt
for RRSO over other risk-reducing options than women who received a 10% risk result based on
multifactorial SNPs + lifestyle factors (31.4% vs. 26.2%, respectively) (χ2(1) = 2.512, p = 0.13).
2.5. EPPM Variables
The mean (M) and standard deviation (SD) of the EPPM variables were: perceived risk (M = 3.51,
SD = 0.82), perceived severity (M = 4.52, SD = 0.58), perceived response-efficacy (M = 4.03, SD = 0.78),
perceived self-efficacy (M = 2.98, SD = 1.34). Means by exposure group are shown in the Supplementary
Materials (Table S2).
2.6. Intention to Have Risk-Reducing Surgery (RRSO) versus Other Risk-Management Options
A binary logistic regression was conducted to investigate what factors were associated with
hypothetical intention to have risk-reducing surgery vs. other behavioural options. Independent
variables included in the model were age, ethnicity, educational attainment, previous breast and
cervical screening participation, experimental group and EPPM variables (perceived risk, perceived
severity, self-efficacy, perceived response-efficacy). In unadjusted analyses, women reporting higher
perceived risk of ovarian cancer and higher perceived severity of ovarian cancer (i.e., the perceived
threat variables), and higher surgery self-efficacy and perceived response-efficacy (i.e., variables
relating to perceptions of the risk-reducing behaviour) were more likely than other women to opt
for risk-reducing surgery. In the multivariable model, perceived response-efficacy (odds ratio (OR)
= 2.22; 95% confidence interval (CI): 1.64–3.00) and self-efficacy (OR = 1.90; 95% CI: 1.63–2.22)
remained significantly associated, whereas the perceived threat variables were no longer significantly
associated, with choosing risk-reducing surgery over other behavioural options. None of the measured
socio-demographic or health-related factors were significantly associated with intention to have surgery
(see Table 2).
Table 2. Logistic regression predicting likelihood of intending to have risk-reducing surgery vs. other
behavioural response (n = 1017).
Variable
Intention to Have
Risk-Reducing Surgery
Odds Ratios (95% CI)
Unadjusted Adjusted
Demographic Factors n (%)
Age
45–50 74 (30.3) Ref Ref
51–55 65 (31.9) 1.07 (0.72–1.61) 0.94 (0.51–1.74)
56–60 60 (30.9) 1.03 (0.68–1.55) 1.00 (0.53–1.87)
61–65 49 (26.6) 0.83 (0.55–1.28) 0.62 (0.32–1.19)
66–70 27 (23.7) 0.71 (0.43–1.19) 0.48 (0.14–1.65)
71–75 15 (19.5) 0.56 (0.30–1.04) 0.29 (0.06–1.50)
Ethnicity
White (Any background) 278 (28.6) Ref Ref
Other ethnic group 11 (28.2) 0.98 (0.48–2.00) 1.16 (0.38–3.50)
Educational Attainment
No formal qualifications 16 (24.2) Ref
GCSE/O Levels 111 (31.5) 1.44 (0.79–2.64)
A-Levels or Equivalent 68 (28.1) 1.22 (0.68–2.29)
Undergraduate degree 59 (24.1) 0.99 (0.53–1.87)
Postgraduate degree 28 (30.4) 1.37 (0.67–2.80)
Other 8 (40.0) 2.08 (0.72–6.00)
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Table 2. Cont.
Variable
Intention to Have
Risk-Reducing Surgery
Odds Ratios (95% CI)
Unadjusted Adjusted
Demographic Factors n (%)
Relationship Status
Not married/in a relationship 82 (27.1) Ref
Married/in a relationship 207 (29.2) 1.11 (0.82–1.50)
Health history
Cervical Screening Attendance (n = 807)
Regular 200 (34.2) Ref Ref
Irregular 49 (22.1) 0.59 (0.41–0.85) * 0.67 (0.41–1.11)
Breast Screening Attendance (n = 741)
Regular 205 (34.6) Ref Ref
Irregular 35 (23.6) 0.53 (0.36–0.80) * 0.67 (0.38–1.17)
Menopause status
Pre-menopause 35 (28.9) Ref Ref
Peri/Post-menopause 243 (28.1) 0.96 (0.63–1.46)
Extended Parallel Processing Model Variables
Perceived Risk 1.43 (1.19–1.71) ** 1.14 (0.90–1.45)
Perceived Severity 1.42 (1.11–1.82) * 1.08 (0.74–1.57)
Self-Efficacy 2.19 (1.94–2.47) ** 1.90 (1.63–2.22) **
Perceived Response Efficacy 3.15 (2.50–3.96) ** 2.22 (1.64–3.00) **
Experimental condition
5% SNPs & Lifestyle 95 (32.8) Ref Ref
10% SNPS & Lifestyle 90 (31.0) 0.92 (0.66–1.29) 1.08 (0.67–1.73)
10% rare genetic variant 105 (36.2) 1.18 (0.85–1.65) 1.87 (1.17–3.00) **
** Predictor significant at the 0.01 level (2-tailed), * Predictor significant at the 0.05 level (2-tailed), CI = Confidence
Interval. Ref = reference category.
3. Discussion
A high proportion (83%) of women in this sample indicated they would be interested in having
an ovarian cancer risk assessment if offered by their GP on the NHS. This is consistent with previous
research by Meisel et al. (2016), who found that 88% of a general population sample of women in
the UK would be interested in genetic testing for ovarian cancer risk if it were offered by the NHS,
and included information about breast cancer risk, echoing previous support from qualitative research
for the availability of genetic testing and risk-stratified screening [43]. It is also consistent with uptake
of genetic testing in our population-based studies [12,21].
We also found that a substantial proportion of British women over the age of 45 years might be
open to the idea of having RRSO, even if their absolute lifetime risk were increased from a general
population risk of 2% to as little as 5% or 10%. In addition, we also demonstrated in multivariable
analyses that perceptions of risk-reducing surgery (self-efficacy and perceived response-efficacy) were
independently associated with choosing surgery over other options, whereas the perceived threat of
ovarian cancer (perceived risk and perceived severity) was not.
Although over a quarter (29%) of women opted for RRSO, slightly more women opted for
surveillance (34%). The observed preference for surveillance may be due to the invasiveness of
surgery, and could also potentially be due to the generally positive attitude towards cancer screening
in the UK [44]. Lack of detailed information on the efficacy of each risk management option due
to the hypothetical nature of this study may have resulted in participants deciding on the less
invasive option, i.e., surveillance. Research suggests perceptions about risk-reducing surgery and
surveillance are potentially modifiable: Mai et al. (2017) identified misperceptions about ovarian
cancer risk and benefits of screening as important factors influencing decisions about risk-reducing
surgery versus surveillance [45]. The concept of common genetic variants of low penetrance single
nucleotide polymorphisms (SNPs) may be unfamiliar to the majority of individuals in the general public.
For example, in a study by French et al. (2018), there was considerable variation in understanding of test
results. The role of SNPs in cancer risk may be less familiar to individuals than more widely publicised
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rare genetic variants such as those in the BRCA genes [40]. Additionally, lifestyle factors may be
perceived as being under greater personal control and, therefore, less serious than rare genetic variants.
Our study findings suggest that individuals interpreted the two levels of risk (5% vs. 10%)
similarly, with the difference in communicated risk having a non-significant impact on participants’
intentions to have RRSO. This supports previous research exploring the effect of risk information
on behaviour, suggesting there is not a simple linear relationship between increments in risk and
risk perception [39,40].
In addition to the lack of impact on perceived risk of ovarian cancer, we similarly found that different
presentations of risk in the hypothetical scenarios (5% SNPs + lifestyle vs. 10% SNPs + lifestyle risk;
10% rare genetic variant vs. 10% SNPs + lifestyle) did not lead to differences in any other cognitive
factors considered in the EPPM framework (i.e., perceived severity of ovarian cancer, perceived
response-efficacy of risk-reducing surgery, self-efficacy to undertake risk-reducing surgery).
In contrast, we found that, in the sample overall, opting for risk-reducing surgery was associated
with higher self-efficacy and higher perceived response-efficacy of risk-reducing surgery. According to
the Extended Parallel Processing Model [46], higher perceptions of self-efficacy and/or response-efficacy
relating to the recommended behaviour are associated with greater likelihood that systematic processing
of threatening (risk) information will occur. Conversely, when perceptions of efficacy are low, people are
more likely to avoid threatening risk information. Together, our findings suggest that if women perceive
or believe that RRSO is being recommended to them clinically, this may have a greater impact on their
decision-making than the details of their risk result (i.e., whether their risk is 5% or 10%, and whether
that risk is based on a single rare genetic variant or a more complex combination of SNPs and lifestyle
factors). The observation that psychological variables had a greater impact on intentions than the
absolute risk numbers suggest that this might be important to consider in any potential future national
rollouts. Offering psychological support for those who need it as part of the RRSO discussion and
decision-making process is part of routine clinical practice in many centres today. Our study highlights
the importance of incorporating this into future national guidelines.
In previous research using hypothetical scenarios, there has been some evidence to suggest that
genetic information leads to more deterministic responses than non-genetic information [33,38,47–49].
Our study did not include a non-genetic condition and so does not speak to this aspect of how people
respond to personal genetic versus non-genetic information.
The present study had several limitations. The cross-sectional design of the study did not allow for
causation to be inferred. However, exploratory experimental studies such as this one can be valuable
in informing hypotheses before moving on to study designs designed to trial real risk assessments.
The use of hypothetical scenarios was both a strength and a limitation. This study attempted to
model a “real life” scenario in which genetic risk information was provided to the general population.
However, many of the contextual details and additional resources that accompany risk information
are not available in hypothetical scenarios, which may limit the ecological validity of the study.
This study was concerned with behavioural intention, as ovarian cancer population surveillance or
population-wide genetic testing is not currently clinically available, so actual behaviour could not be
measured. The presence of a potential intention behaviour gap is well established for other clinical
interventions and cannot be excluded here.
The measures used in this study are adapted from previous research; however, they were almost
all single-item measures, which may not be sensitive enough to adequately represent the underlying
construct being measured due to the lack of psychometric information (e.g., test-retest reliability,
discriminant or convergent validity). Prior knowledge may have an influence on how individuals
appraise threatening health information [50]: this study did not measure previous ovarian cancer and
genetic risk knowledge or previous genetic testing, which may have had an impact on behavioural
intention (however this may be unlikely given this type of genetic testing is not widely available in the
UK). In addition, we did not assess understanding of the information provided, and it is possible that
some concepts (e.g., SNPs) may not have been well understood.
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The sample was predominately White British and, therefore, may not be generalisable to other
ethnic groups, given decisions about risk-reducing surgery and psychological effects may differ
cross-culturally. In addition, the restricted age-range of the sample limits the generalisability of the
findings (e.g., to younger women age 35 years and over who may also be offered risk-reducing surgery
if they are at high risk). However, most women from the general population who are at increased
risk of ovarian cancer will fall in the intermediate risk (5–10% lifetime risk) category [9]. RRSO at
intermediate ovarian cancer risk levels (including for moderate penetrance CSGs) is recommended
to be undertaken over the age of 45–50 years [15]. The sample was self-selected and may have had
greater interest in the topic than the wider general population; the generalizability of the findings is
therefore uncertain. Finally, as with any experimental study, we are unable to rule out the possibility of
demand characteristics, i.e., participants responding in a way they think is expected according to their
perceptions of the aim of the study. Despite the limitations, this study provides insights on the effects
of experimentally manipulating genetic risk information for ovarian cancer on outcomes, comparing
different sources and levels of risk on risk management behavioural intentions and psychological
variables in the general population.
The information provided before being exposed to the hypothetical risk scenario on ovarian
cancer, risk factors, and the efficacy of risk management was necessarily basic and brief, which may
be an additional limitation. However, previous research did not find any difference in behavioural
outcomes between use of gist and extended versions of decision aids in relation to ovarian cancer
risk management [51]. Future research might usefully provide more detailed information containing
details about the efficacy of a particular risk management behaviour to encourage “danger control”
cognitive processing. This may aid in changing risk management preferences.
Future research might also benefit from including measures of other psychological and cognitive
factors as potential predictors of risk management, e.g., causal beliefs. In addition, further research is
needed on communicating risk information incorporating genetics to people in the general population
outside of traditional clinical genetics department settings. Furthermore, a control group where
participants are given a general population-based risk estimate would be useful for future research,
as we were unable to compare between the general population risk and increased risk in this study.
The mean age of participants in this study was 57 years, with the majority of participants having
completed having children and/or being past childbearing age, with most participants reporting they
had begun menopause or were post-menopausal. Future research should explore the psychological
and cognitive effects of ovarian cancer risk information being offered to younger women. In addition,
there were relatively few women in the oldest age group (71–75 years) in this study, and so it is possible
the apparent trend of increasing age being less associated with interest in surgery was due to the study
being underpowered. This could also be a topic of investigation in future research.
Risk-reducing surgery, specifically RRSO, is at present the most effective risk management option
available to women at increased risk of ovarian cancer. Our findings suggest there are a number of
cognitive factors that influence intention to have ovarian cancer risk-reducing clinical interventions,
beyond perceptions of risk. Future research should explore other possible factors that may have an
impact on decision-making about risk management strategies. It is imperative to identify whether
and/or how genetic risk information about common complex diseases will be translated into public
health benefit: this is arguably especially urgent for diseases, such as ovarian cancer, which are
characterised by being notoriously difficult to detect early and by having a high prevalence of late-stage
diagnosis. Combined testing for multiple genetic factors together with lifestyle and other risk factors
may lead to the ability to stratify the population for ovarian cancer risk for targeted prevention thus
potentially saving lives.
Population testing provides a new paradigm for ovarian cancer prevention and can prevent
thousands more cancers than the current clinical approach [52]. Jewish population studies support
population testing for CSGs [53]. Our pilot study shows that population testing for lifetime risk of
ovarian cancer is feasible, acceptable and has high satisfaction in general population women [12].
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However, there is now need for large implementation studies, with long term outcomes, to provide
real world evidence and develop context-specific models for implementing this approach for women in
the general population. This will valuably inform future policy decisions regarding population-wide
risk stratified approaches for risk-adapted ovarian cancer screening and prevention.
4. Materials and Methods
4.1. Overview
Participants (n = 1017) were women aged 45–75 years recruited via online survey company Survey
Sampling International (SSI) in July 2017. An email containing a web link was sent to SSI panellists
who fit the study criteria with respect to gender and age, inviting them to take part. The email did not
contain information about the topic of the study. Those responding were directed to a short screening
questionnaire. Eligible participants were then presented with a consent form. Incentive points, which
can be exchanged for shopping vouchers, were awarded to SSI panellists for their time (equivalent to
~£0.50 for this 10 min study).
All participants were given information about ovarian cancer, including that on average around
2% of women will develop ovarian cancer in their lifetime; asked to imagine that they had had an
ovarian cancer risk assessment via the NHS; and asked to imagine they had received a result indicating
they were at increased risk of ovarian cancer (see Appendix A).
Women were randomly assigned to one of three experimental conditions using a software
algorithm (See Figure 1). They were asked to imagine they had undergone an ovarian cancer risk
assessment and had received this personalised risk estimate from their GP: (a) 5% ovarian cancer risk
due to common genetic variants and lifestyle factors; (b) 10% ovarian cancer risk due to common
genetic variants and lifestyle factors; or (c) 10% ovarian cancer risk due to a single rare variant in a
cancer susceptibility gene such as BRCA2 (see Appendix B).
The study was approved by the University College London ethics committee (Project
ID Number: 10251/001).
4.2. Inclusion Criteria
Eligible participants were women aged 45–75 years, with no previous history of breast or ovarian
cancer diagnosis. Women who indicated they were unsure of, or had not completed childbearing,
were excluded from analyses (n = 13).
4.3. Measures
All measures are shown in Appendix C.
4.3.1. Interest in Ovarian Cancer Risk Assessment
Interest was assessed before exposure to the hypothetical test results, with the item, “If your GP
offered you this ovarian cancer risk assessment on the NHS, would you take up the offer?” (adapted
from [20]. Response options were “no, definitely not”; “no probably not”; “yes, probably” and “yes,
definitely”. The information women read before answering the question explained that the risk
assessment would involve providing lifestyle information as well as a blood sample for genetic testing
(see Appendix A).
4.3.2. Perceived Risk of Ovarian Cancer
Perceived risk was measured using a single item, “If I had just received this personal ovarian
cancer risk result, I would feel that my risk of developing ovarian cancer was” adapted from [54].
Responses for these questions were recorded on a 5-point Likert scale with response options ranging
from “much lower than other women of my age” to “much higher than women of my age”. A higher
score on the 5-point scale indicated greater perceived risk.
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4.3.3. Perceived Severity of Ovarian Cancer
Perceived severity was measured using two questions adapted from [55]: “Developing ovarian
cancer would have major consequences on my life” and “ovarian cancer is a serious condition” with
five response options ranging from “strongly agree” to “strongly disagree”. A higher score on the
(possible scores 1–5) scale indicated greater perceived severity.
4.3.4. Self-Efficacy for Risk-Reducing Surgery
One item, adapted from [56], assessed participants’ confidence in their ability to have risk-reducing
surgery. Individuals were asked “How confident are you that you would go through with risk-reducing
surgery if you were motivated to do so”. The response options ranged from “not at all confident” to
“extremely confident”. A higher score on the scale indicated greater perceived self-efficacy.
4.3.5. Perceived Response-Efficacy of Risk-Reducing Surgery
For perceived response-efficacy of risk-reducing surgery, participants were asked to indicate how
effective they felt risk-reducing surgery would be in lowering their ovarian cancer risk using a single
item adapted from [56]: “Having surgery to remove your ovaries and fallopian tubes is an effective
way to lower your risk of ovarian cancer”. The response options were “strongly agree” to “strongly
disagree”. Items were reverse coded: a higher score on the (possible scores 1–5) scale indicated greater
perceived response-efficacy.
4.3.6. Behavioural Intention
To assess women’s potential behavioural reactions to their risk results, they were asked: “If I had
just received this personal ovarian cancer risk result, I would choose to...”. The response options were:
“have risk-reducing surgery to remove my ovaries”; “have surveillance such as regular ultrasound
scans”; “make lifestyle changes”; “do nothing”; and “I am not sure what I would do”.
4.3.7. Demographic and Health Characteristic Measures
Information on demographics was collected from all participants including: age, ethnicity,
educational attainment, relationship status, health characteristics, family history of cancer, personal
history of cancer, menopause status, and breast and cervical screening attendance. Ethnicity (White
vs. other ethnic group), menopause status (pre-menopausal vs. peri/post-menopause) and breast and
cervical screening attendance (regular vs. irregular or not yet eligible) were dichotomised.
4.4. Data Analyses
A power calculation based on the primary binary outcome, intention to have risk-reducing
surgery, taking into account group comparisons of three groups, suggested a sample size of 782 was
required (medium effect size, power of 90%, alpha of 0.05). All statistical analyses of the data were
carried out using SPSS 24. Analyses of variance (ANOVAs) and chi-square tests were conducted to
explore between-group differences. Logistic regression was used to explore predictors of willingness
to have risk-reducing surgery (vs. other behavioural responses to the risk information). Unadjusted
and adjusted models were examined to explore the predictive effect of the experimental group
and psychological variables on intention to have surgery and address possible demographic and
health-related covariates.
5. Conclusions
The findings of this study contribute to a growing body of risk stratification research exploring
the potential usefulness and clinical utility of population-wide risk assessment incorporating genetic
testing alongside other risk factors. The need for risk stratification is perhaps particularly urgent for
diseases, such as ovarian cancer, where survival outcomes are poor and population-wide screening for
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the disease is not currently recommended. We provide initial evidence, suggesting that a substantial
proportion of women aged 45 years and over are open to the idea of risk stratification and having
surgery to reduce their risk of ovarian cancer in response to increased risk results, even if their absolute
lifetime risk is only increased by a few percentage points in absolute terms. Our findings do not speak
to other barriers that might prevent women’s behavioural intentions or preferences being translated
into actions—barriers such as lack of timely access to healthcare services.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/12/3543/s1,
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Appendix A
Ovarian cancer and risk information
Section 1: Hypothetical scenario
Please imagine that you have gone to your GP, and they have offered you a new approach to assessing your
risk of developing ovarian cancer in the future. When your GP offered this to you, they gave you some written
information to help you decide whether or not you want to have the risk assessment done. This information is
below. Please read the information, and then answer the question that follows.
Assessing ovarian cancer risk
Ovarian cancer is the sixth most common cancer among women in the UK: 2% of women will be diagnosed
with ovarian cancer during their lifetime. Ovarian cancer is caused by many genetic and non-genetic factors.
Currently, ovarian cancer is often detected at a late stage because symptoms are hard to spot. This means that it
is often very hard to treat effectively.
A new ovarian cancer risk assessment has been developed. This risk assessment combines lots of different
types of information about you to estimate how likely you are to develop ovarian cancer in your lifetime.
The types of information included in the risk assessment include lifestyle factors, rare genetic variants,
and common genetic variants.
Lifestyle factors: Lifestyle factors that may increase a woman’s risk of ovarian cancer include tobacco smoking
and being overweight.
Common genetic variants: Single nucleotide polymorphisms, frequently called SNPs (pronounced “snips”),
are the most common type of genetic variation among people. SNPs occur normally throughout a person’s
DNA. Most SNPs have no effect on health, but some are important to a person’s health. Some SNPs can
influence a woman’s risk of developing ovarian cancer. Individually, each one of these SNPs only influences
ovarian cancer risk by a tiny amount, but if a woman has a large number of these SNPs then her risk of ovarian
cancer may be increased.
Rare genetic variants: Some ovarian cancers are caused by a rare variant in a person’s DNA. These rare
variants can have quite a strong effect on a woman’s risk of developing ovarian cancer. For example, variants
in the BRCA2 gene can increase a woman’s lifetime risk of ovarian cancer up to between 10% and 20%.
If you want to have this ovarian cancer risk assessment carried out, you will need to provide your GP with the
information they request, including about your lifestyle. You will also need to have a blood test, so that the
scientists can see whether you have any of the genetic variants that increase your risk.
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Appendix B
Generic Risk Scenarios
Next, regardless of how you answered in the previous question, please imagine that you have had the
ovarian cancer risk assessment done, and your GP has now given you the result from the assessment. Please
read your hypothetical result below.
Your personal ovarian cancer risk assessment: results [Group 1 only]
Your result indicates that your lifetime risk of developing ovarian cancer is 5%. This is higher than the average
risk for women, which is 2%.
Your risk of ovarian cancer is higher than average because you have been found to have at least one
lifestyle factor and several common genetic variants which are known to put women at increased risk of
developing ovarian cancer.
OR
Your personal ovarian cancer risk assessment: results [Group 2 only]
Your result indicates that your lifetime risk of developing ovarian cancer is 10%. This is higher than the
average risk for women, which is 2%.
Your risk of ovarian cancer is higher than average because you have been found to have at least one
lifestyle factor and several common genetic variants which are known to put women at increased risk of
developing ovarian cancer.
OR
Your personal ovarian cancer risk assessment: results [Group 3 only]
Your result indicates that your lifetime risk of developing ovarian cancer is 10%. This is higher than the
average risk for women, which is 2%.
Your risk of ovarian cancer is higher than average because you have been found to have a rare genetic variant
which is known to put women at increased risk of developing ovarian cancer.
AND
[All groups]
There are several options for women who are at higher than average risk of ovarian cancer.
Risk-reducing surgery involves removing the ovaries and fallopian tubes to prevent ovarian cancer from
developing. However, removing the ovaries has downsides. For example, it causes a woman who has not yet
been through her menopause to start her menopause (a natural process that usually happens in a woman’s
early 50 s).
Surveillance includes having a regular (e.g., annual) ultrasound of your ovaries to see if a tumour is present.
This ultrasound is usually an internal (transvaginal) ultrasound. Effective screening has not been established.
Lifestyle changes include maintaining a healthy weight and quitting smoking. These types of lifestyle changes
may reduce a woman’s risk of developing ovarian cancer.
Appendix C
Questionnaire
Please carefully imagine what you would think and how you would feel if you had received this personal
result from the ovarian cancer risk assessment. Now please answer the following questions.
Intention for Genetic Screening
Q1. If your GP offered you this ovarian cancer risk assessment on the NHS, would you take up
the offer?
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• No definitely not
• No probably not
• Yes probably
• Yes definitely
Q2. How likely do you think you are to develop ovarian cancer in your lifetime?
(a) . . . Not at all likely
(b) . . . Not very likely
(c) . . . Quite likely
(d) . . . Extremely likely
Behavioural outcome
Q3. If I had just received this personal ovarian cancer risk result, I would choose to . . .
(a) . . . have risk-reducing surgery to remove my ovaries.
(b) . . . have surveillance such as regular ultrasound scans.
(c) . . . make lifestyle changes.
(d) . . . do nothing.
(e) . . . I am not sure what I would choose.
(Please select one option only)
Perceived risk
Q4. If I had just received this personal ovarian cancer risk result, I would feel that my risk of
developing ovarian cancer was . . .
(a) . . . much lower than other women of my age
(b) . . . lower than other women of my age
(c) . . . the same as other women of my age
(d) . . . higher than other women of my age
(e) . . . much higher than other women of my age
Perceived Response efficacy
How much do you agree or disagree with the following statement based on how you would feel if you had
received this personal ovarian cancer risk result from the ovarian cancer risk assessment.
Q7. There is little that can be done to prevent ovarian cancer.
(a) . . . Strongly agree
(b) . . . Agree
(c) . . . Neither agree or disagree
(d) . . . Disagree
(e) . . . Strongly disagree
Q8. Having surgery to remove your ovaries and fallopian tubes is an effective way to lower your
risk of ovarian cancer.
(a) . . . Strongly agree
(b) . . . Agree
(c) . . . Neither agree or disagree
(d) . . . Disagree
(e) . . . Strongly disagree
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Perceived Response efficacy
Q9. Regular screening through transvaginal ultrasound is an effective way to lower your risk of
ovarian cancer.
(a) . . . Strongly agree
(b) . . . Agree
(c) . . . Neither agree or disagree
(d) . . . Disagree
(e) . . . Strongly disagree
Perceived severity
Q10. Developing ovarian cancer would have major consequences on my life
(a) . . . Strongly agree
(b) . . . Agree
(c) . . . Neither agree or disagree
(d) . . . Disagree
(e) . . . Strongly disagree
Perceived severity
Q11. Ovarian cancer is a serious condition.
(a) . . . Strongly agree
(b) . . . Agree
(c) . . . Neither agree or disagree
(d) . . . Disagree
(e) . . . Strongly disagree
Self-efficacy
Q12. How confident are you that you could go through with having risk-reducing surgery if you
were motivated to do so?
(a) . . . not at all confident
(b) . . . somewhat confident
(c) . . . fairly confident
(d) . . . very confident
(e) . . . extremely confident
Q13. Have you ever been diagnosed with cancer? (Please select one)
Yes
No
Not sure
Q14. If yes, what type of cancer is it/was it?
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Q15. Do you have a family history of cancer?
Have anyfirst-degree family member(parents, brothers, sisters, children) orsecond-degree(aunts, uncles, nieces,
nephews, grandparents, grandchildren) been diagnosed with cancer.
Yes
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No
Not sure
Q15a. If yes, what type(s) of cancer?
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ..
Q16. What is your current menstrual status? (Please select one)
Premenopausal (before menopause; having regular periods)
Perimenopause (menopause transition—changes in periods, but have not gone 12 months in a row
without a period)
Postmenopausal (After menopause; periods have stopped for at least 12 months)
Don’t know
Q17. If you have indicated that you have not had a period in the previous 12 months, what age
were you at your last period?
Q18. If you are still having periods, how often do they occur? (Please respond in days)
Q19. Is there a recent change in how often you have periods?
Yes/No
Q20. Was your menopause:
Spontaneous (“natural”)
Surgical (removal of both ovaries)
Due to chemotherapy or radiation therapy
Other
n/a—haven’t yet reached menopause
(If indicated they are still having periods don’t ask this question)
Q21. Women aged 25–49 years are invited for cervical screening (also called a smear or Pap test)
every 3 years, and women aged 50–64 are invited every 5 years. Which of these statements best
describes you?
I’m up to date with cervical screening
I’m overdue for cervical screening
I’ve never been for cervical screening
I’m 65 or over so I’m not invited any more
Q22. Women aged 50–70 years are invited for breast screening (also called a mammogram or
mammography) every 3 years. Which of these statements best describes you?
I’m up to date with breast screening
I’m overdue for breast screening
I’ve never been for breast screening
I’m under 50 or over 70 so I’m not eligible for breast screening.
Q23. How old are you?
__________________
Q24. How would you describe your ethnic background? (Please select one)
White British
White non-British
Cancers 2020, 12, 3543 18 of 21
Black
Asian
Mixed
Other
Do not wish to answer
Q25. What is the highest level of education you have achieved? (Please select one)
No formal qualifications
GCSEs/O levels or equivalent
A-Levels or equivalent
Undergraduate degree or equivalent
Postgraduate degree or equivalent
Other (please state)
Q26. What is your relationship status? (Please select one)
Single
In a relationship
Living with a partner
Married
Separated/divorced/widowed
Q27. How many children do you have? (Please select one)
0
1
2
3
4
5 or more
Q28. Do you plan to have any (more) children in the future? (Please select one)
Yes
No
Not sure
END OF SURVEY
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